JonesTrading Upgrades Relay Therapeutics (NASDAQ:RLAY) to Strong-Buy

Posted by Brian Himes on May 21st, 2026

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) was upgraded by equities researchers at JonesTrading from a “hold” rating to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

RLAY has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a report on Wednesday, April 8th. Raymond James Financial reissued a “strong-buy” rating on shares of Relay Therapeutics in a report on Tuesday. Wells Fargo & Company raised their price objective on Relay Therapeutics from $17.00 to $21.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. UBS Group set a $26.00 price objective on Relay Therapeutics in a report on Tuesday. Finally, Citizens Jmp lifted their price objective on Relay Therapeutics from $19.00 to $21.00 and gave the stock a “market outperform” rating in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $22.60.

Check Out Our Latest Stock Report on Relay Therapeutics

Relay Therapeutics Stock Up 7.9%

Relay Therapeutics stock opened at $13.02 on Tuesday. The firm has a market cap of $2.49 billion, a price-to-earnings ratio of -8.29 and a beta of 1.74. Relay Therapeutics has a 52 week low of $2.75 and a 52 week high of $17.32. The business’s 50-day moving average price is $12.62 and its 200 day moving average price is $9.66.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $3.00 million during the quarter, compared to the consensus estimate of $5.58 million. Equities analysts expect that Relay Therapeutics will post -1.6 EPS for the current year.

Insider Buying and Selling

In related news, CFO Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $12.86, for a total transaction of $227,840.62. Following the transaction, the chief financial officer owned 195,178 shares in the company, valued at approximately $2,509,989.08. This trade represents a 8.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 40,449 shares of company stock worth $532,889 in the last quarter. Company insiders own 5.04% of the company’s stock.

Hedge Funds Weigh In On Relay Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC raised its position in Relay Therapeutics by 591.7% in the fourth quarter. SG Americas Securities LLC now owns 220,949 shares of the company’s stock valued at $1,869,000 after purchasing an additional 189,004 shares during the period. Tudor Investment Corp ET AL purchased a new stake in Relay Therapeutics in the third quarter valued at $399,000. Commodore Capital LP raised its position in Relay Therapeutics by 27.3% in the third quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock valued at $88,740,000 after purchasing an additional 3,650,000 shares during the period. Sanctuary Advisors LLC purchased a new stake in Relay Therapeutics in the fourth quarter valued at $1,203,000. Finally, Mayport LLC purchased a new stake in Relay Therapeutics in the third quarter valued at $259,000. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Trending Headlines about Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

Positive Sentiment: Relay reported encouraging Phase 2 ReInspire data for zovegalisib in PIK3CA-driven vascular anomalies, including a 60% volumetric response rate across doses, broad symptom improvement, and a tolerability profile that could support chronic use. GlobeNewswire release on initial clinical data
Positive Sentiment: Reuters and other market coverage highlighted that the mid-stage results showed the experimental treatment can shrink vascular malformations and improve symptoms, reinforcing investor optimism around the drug’s commercial potential. Reuters article
Positive Sentiment: Analysts responded favorably, with Citizens JMP raising its price target to $21 and Raymond James lifting its target to $26, while both kept bullish ratings. Analyst price target updates via Benzinga
Neutral Sentiment: Unusually heavy options activity showed traders positioning for more volatility, with a sharp rise in put volume suggesting some caution even as the stock rallied.
Negative Sentiment: Relay announced a proposed $175 million common stock offering, which can pressure the share price in the near term due to dilution concerns, even though it also strengthens the balance sheet. GlobeNewswire offering announcement

Relay Therapeutics Company Profile

(Get Free Report)

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.